化浊去瘀方治疗非酒精性脂肪肝临床研究

Clinical Observation on Turbidity-resolving and Stasis-removing Prescription for the Treatment of Nonalcoholic Fatty Liver Disease

【目的】探讨化浊去瘀方治疗非酒精性脂肪肝病的临床疗效。【方法】选择113例非酒精性脂肪肝患者,按就诊顺序随机分为中药组61例和对照组52例。中药组给予化浊去瘀方治疗,每次口服100 mL,2次/d;对照组给予熊去氧胆酸(UDCA)口服,150 mg/次,3次/d。疗程均为2个月。【结果】中药组总有效率为85.2%,优于对照组的51.9%(P<0.05);中药组患者B超影像改善,其复常率为31.1%,优于对照组的9.6%(P<0.05);两组血清丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)治疗后均有所降低,与治疗前比较差异有显著性意义(P<0.01),说明两组治疗方案均能有效改善肝功能;中药组在改善血中总胆固醇(TC)、低密度脂蛋白胆固醇(LDC-C)、高密度脂蛋白胆固醇(HDL-C)水平方面优于对照组(P<0.01)。【结论】化浊去瘀方可有效治疗非酒精性脂肪肝。

[Objective] To investigate the therapeutic effect of Turbidity-resolving and Stasis-removing Prescription （TSP） for the treatment of nonalcoholic fatty liver disease （NFLD）. [ Methods] One hundred and thirteen NFLD patients were randomized into groups A and B according to their consulting order. Group A （ N = 61） received oral use of TSP 100 mL, bid, and group B （N = 52） received oral use of ursodesoxycholic acid （UDCA） 150 mg, tid. The treatment lasted 2 months. [Results] The total effective rate was 85.2% in group A, superior to 51.9% in group B （ P 〈 0.05）. The normalization rate of B-ultrasonic irrkage was 31.1% in group A, superior to 9.6% in group B （ P 〈 0.05）. Serum levels of alanine aminotransferase （ALT） and aspartate aminotransferase （AST） were decreased in the two groups after treatment （ P 〈 0.01 compared with those before treatment）, indicating that both TSP and UDCA improved the hepatic function. In improving serum levels of cholesterol, low-density lipoprotein cholesterol （LDLC） and highdensity lipoprotein cholesterol （HDLC）, Group A had a better effect than group B （P 〈 0.01）. [Conclusion] TSP is effective for the treatment of NFLD.